aDepartment of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK bDepartment of Neurology, King's College Hospital National ...
Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker and renal findings from the MODIFY Phase 3 ...
Courtesy of Nivalon Medical Technologies Inc. YOUNGSTOWN, Ohio, Jan. 29, 2026 /PRNewswire/ — Nivalon Medical Technologies Inc. has successfully produced the world’s first fully patient-specific, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results